Syndax Pharmaceuticals, Inc.
SNDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSyndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. With a market capitalization of $2.08B, it sits in mid-cap territory. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Market Cap
$2.08B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
-44.85
EPS (TTM)
$-2.72
EPS (Fwd)
$-0.52
ROE
-189.5%
ROA
-25.1%
Cash
$361.2M
Total Debt
$345.4M
Free CF
-$186.0M
52W Change
154.3%
Annual Financials
Cash vs Debt
With $361.2M in cash and $345.4M in debt, SNDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$186.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -189.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.37 suggests SNDX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Syndax Pharmaceuticals, Inc.'s trajectory.